Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.
Saved in:
| Title: | Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. |
|---|---|
| Authors: | Hong SD; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wang YS; West China Hospital of Sichuan University, Chengdu, China., Zhao HY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhao YY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wang QM; Henan Cancer Hospital, Zhengzhou, China., Ma YX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Li YS; Chongqing Cancer Hospital, Chongqing, China., Huang Y; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Yang YP; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Fu ZM; Renmin Hospital of Wuhan University, Wuhan, China., Chen LK; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhou F; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China., Yang J; The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li XY; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Hou X; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhou NN; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Sun LH; The First Affiliated Hospital of Nanchang University, Nanchang, China., Zhang GF; Xinxiang Central Hospital, Xinxiang, China., Cui JW; The First Hospital of Jilin University, Changchun, China., Wu L; Hunan Provincial Cancer Hospital, Changsha, China., Chen G; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Zhang YX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China., Wang HY; Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China., Lv DQ; Taizhou Hospital of Zhejiang Province, Taizhou, China., Shi JH; Linyi Cancer Hospital, Linyi, China., Jiang B; Yunnan Cancer Hospital, Kunming, China., Li C; Changzhou First People's Hospital, Changzhou, China., Li XL; Liaoning Cancer Hospital & Institute, Shenyang, China., Tang KJ; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Yu Y; Harbin Medical University Cancer Hospital, Harbin, China., Ji YH; The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China., He ZY; Fujian Cancer Hospital, Fuzhou, China., Zhu Y; Sichuan Biokin Pharmaceutical Co. Ltd, Chengdu, China., Zhu H; Sichuan Biokin Pharmaceutical Co. Ltd, Chengdu, China., Xiao S; Baili-Bio (Chengdu) Pharmaceutical Co. Ltd, Chengdu, China., Zhou CC; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: caicunzhoudr@163.com., Zhang L; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. Electronic address: zhangli@sysucc.org.cn., Fang WF; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. Electronic address: fangwf@sysucc.org.cn. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Jun; Vol. 37 (6), pp. 813-824. Date of Electronic Publication: 2026 Jan 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41611210 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hong+SD%22">Hong SD</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wang+YS%22">Wang YS</searchLink>; West China Hospital of Sichuan University, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Zhao+HY%22">Zhao HY</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhao+YY%22">Zhao YY</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wang+QM%22">Wang QM</searchLink>; Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Ma+YX%22">Ma YX</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Li+YS%22">Li YS</searchLink>; Chongqing Cancer Hospital, Chongqing, China.<br /><searchLink fieldCode="AU" term="%22Huang+Y%22">Huang Y</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Yang+YP%22">Yang YP</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Fu+ZM%22">Fu ZM</searchLink>; Renmin Hospital of Wuhan University, Wuhan, China.<br /><searchLink fieldCode="AU" term="%22Chen+LK%22">Chen LK</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhou+F%22">Zhou F</searchLink>; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yang+J%22">Yang J</searchLink>; The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Li+XY%22">Li XY</searchLink>; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Hou+X%22">Hou X</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhou+NN%22">Zhou NN</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Sun+LH%22">Sun LH</searchLink>; The First Affiliated Hospital of Nanchang University, Nanchang, China.<br /><searchLink fieldCode="AU" term="%22Zhang+GF%22">Zhang GF</searchLink>; Xinxiang Central Hospital, Xinxiang, China.<br /><searchLink fieldCode="AU" term="%22Cui+JW%22">Cui JW</searchLink>; The First Hospital of Jilin University, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Wu+L%22">Wu L</searchLink>; Hunan Provincial Cancer Hospital, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Chen+G%22">Chen G</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+YX%22">Zhang YX</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wang+HY%22">Wang HY</searchLink>; Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China.<br /><searchLink fieldCode="AU" term="%22Lv+DQ%22">Lv DQ</searchLink>; Taizhou Hospital of Zhejiang Province, Taizhou, China.<br /><searchLink fieldCode="AU" term="%22Shi+JH%22">Shi JH</searchLink>; Linyi Cancer Hospital, Linyi, China.<br /><searchLink fieldCode="AU" term="%22Jiang+B%22">Jiang B</searchLink>; Yunnan Cancer Hospital, Kunming, China.<br /><searchLink fieldCode="AU" term="%22Li+C%22">Li C</searchLink>; Changzhou First People's Hospital, Changzhou, China.<br /><searchLink fieldCode="AU" term="%22Li+XL%22">Li XL</searchLink>; Liaoning Cancer Hospital & Institute, Shenyang, China.<br /><searchLink fieldCode="AU" term="%22Tang+KJ%22">Tang KJ</searchLink>; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Yu+Y%22">Yu Y</searchLink>; Harbin Medical University Cancer Hospital, Harbin, China.<br /><searchLink fieldCode="AU" term="%22Ji+YH%22">Ji YH</searchLink>; The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.<br /><searchLink fieldCode="AU" term="%22He+ZY%22">He ZY</searchLink>; Fujian Cancer Hospital, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhu+Y%22">Zhu Y</searchLink>; Sichuan Biokin Pharmaceutical Co. Ltd, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Zhu+H%22">Zhu H</searchLink>; Sichuan Biokin Pharmaceutical Co. Ltd, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Xiao+S%22">Xiao S</searchLink>; Baili-Bio (Chengdu) Pharmaceutical Co. Ltd, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Zhou+CC%22">Zhou CC</searchLink>; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: caicunzhoudr@163.com.<br /><searchLink fieldCode="AU" term="%22Zhang+L%22">Zhang L</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. Electronic address: zhangli@sysucc.org.cn.<br /><searchLink fieldCode="AU" term="%22Fang+WF%22">Fang WF</searchLink>; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. Electronic address: fangwf@sysucc.org.cn. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2026 Jun; Vol. 37 (6), pp. 813-824. <i>Date of Electronic Publication: </i>2026 Jan 27. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41611210 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2026.01.009 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 813 Titles: – TitleFull: Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hong SD – PersonEntity: Name: NameFull: Wang YS – PersonEntity: Name: NameFull: Zhao HY – PersonEntity: Name: NameFull: Zhao YY – PersonEntity: Name: NameFull: Wang QM – PersonEntity: Name: NameFull: Ma YX – PersonEntity: Name: NameFull: Li YS – PersonEntity: Name: NameFull: Huang Y – PersonEntity: Name: NameFull: Yang YP – PersonEntity: Name: NameFull: Fu ZM – PersonEntity: Name: NameFull: Chen LK – PersonEntity: Name: NameFull: Zhou F – PersonEntity: Name: NameFull: Yang J – PersonEntity: Name: NameFull: Li XY – PersonEntity: Name: NameFull: Hou X – PersonEntity: Name: NameFull: Zhou NN – PersonEntity: Name: NameFull: Sun LH – PersonEntity: Name: NameFull: Zhang GF – PersonEntity: Name: NameFull: Cui JW – PersonEntity: Name: NameFull: Wu L – PersonEntity: Name: NameFull: Chen G – PersonEntity: Name: NameFull: Zhang YX – PersonEntity: Name: NameFull: Wang HY – PersonEntity: Name: NameFull: Lv DQ – PersonEntity: Name: NameFull: Shi JH – PersonEntity: Name: NameFull: Jiang B – PersonEntity: Name: NameFull: Li C – PersonEntity: Name: NameFull: Li XL – PersonEntity: Name: NameFull: Tang KJ – PersonEntity: Name: NameFull: Yu Y – PersonEntity: Name: NameFull: Ji YH – PersonEntity: Name: NameFull: He ZY – PersonEntity: Name: NameFull: Zhu Y – PersonEntity: Name: NameFull: Zhu H – PersonEntity: Name: NameFull: Xiao S – PersonEntity: Name: NameFull: Zhou CC – PersonEntity: Name: NameFull: Zhang L – PersonEntity: Name: NameFull: Fang WF IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1569-8041 Numbering: – Type: volume Value: 37 – Type: issue Value: 6 Titles: – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology Type: main |
| ResultId | 1 |
